Therapeutic innovations: targeting ROS production in AML with natural and synthetic compounds

  • Naunyn Schmiedebergs Arch Pharmacol. 2025 Sep;398(9):11387-11406. doi: 10.1007/s00210-025-04054-6.
Mohammed Hashim Mohammed  1 ,  Raed Fanoukh Aboqader Al-Aouadi  2 ,  Subasini Uthirapathy  3 ,  Gaurav Sanghvi  4 ,  Rekha M M  5 ,  Resan Shakir Abdulamer  6 ,  G V Siva Prasad  7 ,  Mayank Kundlas  8 ,  Fayzulla Khamraev  9 ,  Muhammad Ikram Ullah  10
Affiliations
  • 1. Medical Laboratory Techniques Department, College of Health and Medical Technology, Al-Maarif University, Anbar, Iraq. [email protected].
  • 2. College of Medicine, Al-Ayen Iraqi University, AUIQ, An Nasiriyah, Iraq.
  • 3. Pharmacy Department, Tishk International University, Erbil, Kurdistan Region, Iraq.
  • 4. Department of Microbiology, Faculty of Science, Marwadi University Research Center, Marwadi University, Rajkot, 360003, Gujarat, India.
  • 5. Department of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to Be University), Bangalore, Karnataka, India.
  • 6. Department of Medical Laboratories Technology, Al-Nisour University College, Nisour Seq. Karkh, Baghdad, Iraq.
  • 7. Department of Chemistry, Raghu Engineering College, Visakhapatnam, Andhra Pradesh, 531162, India.
  • 8. Centre for Research Impact & Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, 140401, Punjab, India.
  • 9. University of Mining and Technologies, Navoiy, Uzbekistan.
  • 10. Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, 72388, Sakaka, Aljouf, Saudi Arabia.
PMID: 40163149 DOI: 10.1007/s00210-025-04054-6
Abstract

Reactive oxygen species (ROS) play a dual role in the pathophysiology of Acute Myeloid Leukemia (AML), functioning as both signaling molecules and agents of cellular damage. This review offers an in-depth analysis of ROS production in AML, highlighting their impact on essential cellular pathways that govern cell survival, proliferation, and Apoptosis. It explores both natural and synthetic pharmacological agents that modulate ROS generation and enhance oxidative stress, assessing their therapeutic potential and the challenges they present in clinical practice. Additionally, the review identifies ROS-associated prognostic biomarkers that could enhance patient stratification and improve treatment outcomes in AML. Despite the promising potential of ROS-targeted therapies, significant challenges remain, such as the complexity of ROS dynamics, resistance mechanisms, and the influence of the tumor microenvironment. This review aims to shed light on current advancements and emphasize the need for further research to refine therapeutic strategies that leverage the ROS pathway in AML.

Keywords
AML; Cancer therapy; Oxidative stress; ROS.
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-171334A
    P1D-34
    Pin1 PROTAC Degrader
    Research Areas: Cancer